Cargando…
Randomized clinical trial: effect of the 5-HT(4) receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment
BACKGROUND: Approximately, 20–30% of patients with gastro-esophageal reflux disease (GERD) experience persistent symptoms despite treatment with proton pump inhibitors (PPIs). These patients may have underlying dysmotility; therefore, targeting gastric motor dysfunction in addition to acid inhibitio...
Autores principales: | Tack, J, Zerbib, F, Blondeau, K, des Varannes, S B, Piessevaux, H, Borovicka, J, Mion, F, Fox, M, Bredenoord, A J, Louis, H, Dedrie, S, Hoppenbrouwers, M, Meulemans, A, Rykx, A, Thielemans, L, Ruth, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681320/ https://www.ncbi.nlm.nih.gov/pubmed/25530111 http://dx.doi.org/10.1111/nmo.12484 |
Ejemplares similares
-
Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy
por: Shaheen, N. J., et al.
Publicado: (2015) -
Reflux symptoms and oesophageal acidification in treated achalasia patients are often not reflux related
por: Ponds, Fraukje A, et al.
Publicado: (2021) -
Nocturnal Gastroesophageal Reflux Revisited by Impedance-pH Monitoring
por: Fornari, Fernando, et al.
Publicado: (2011) -
Gastroesophageal reflux and PPI exposure alter gut microbiota in very young infants
por: Francis, Denease, et al.
Publicado: (2023) -
Review article: rethinking the “ladder” approach to reflux‐like symptom management in the era of PPI “resistance” ‐ a multidisciplinary perspective
por: Hungin, A. Pali S., et al.
Publicado: (2022)